Skip to content
Tariffs and dutiesCBPUnited StatesImportsExports

Guidance: Section 232 Duties on Imports of Patented Pharmaceutical Articles and Ingredients

30 July 2026

In plain English

CBP guidance implements Presidential Proclamation 11020 imposing Section 232 additional duties on imports of patented pharmaceutical articles and ingredients, effective July 31, 2026 for companies listed in Annex III.

Read the official notice
Topic
Tariffs and duties
Regulator
CBP
Published
30 July 2026
For
Imports and Exports
Where it applies
United States
Source
CBP CSMS

From the notice

The purpose of this message is to provide guidance on the implementation of the April 2, 2026, Presidential Proclamation 11020, Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States . BACKGROUND On April 2, 2026, the President issued Proclamation 11020, imposing additional dut ies on certain imports of patented pharmaceuticals and ingredients for patented pharmaceuticals (active pharmaceutical ingredients and key starting materials). The additional duties on imports of patented pharmaceutical products and ingredients are effective July 31, 2026 for the products of companies listed in Annex III to the P roclamation
The full text is at the source

Olive tells you which of these hit your products.

Olive reads every change like these against your own products, codes and trade lanes, whether you import, export or both, and drafts the update to your compliance program for your approval. Nothing changes without you.

Get startedLive demo

Olivra lists official notices for information only. It is not legal advice, and Olive is not a lawyer or a licensed customs broker. The official text at the source is what counts.

More from CBP

See everything Olive monitors